TICKERNOMICS Sign up
Last Update: 2024-03-28 02:09:40
Legend Biotech Corp ( LEGN ) https://www.legendbiotech.com
55.90USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
LEGN
19.42%
SPY
32.74%
LEGN
99.79%
SPY
92.93%
LEGN
0.00%
SPY
224.41%
LEGN
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
20551.28
20411.42
0.76
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-384.11
89.01
15.34
-1.90
0.00
-49.80
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-96.18
54.72
-135.86
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
-36.98
-27.39
0.00
Other Earnings and Cash Flow Stats:
Legend Biotech Corp ( LEGN ) Net Income TTM ($MM) is 60.67
Legend Biotech Corp ( LEGN ) Operating Income TTM ($MM) is -23.60
Legend Biotech Corp ( LEGN ) Owners' Earnings Annual ($MM) is -365.26
Legend Biotech Corp ( LEGN ) Current Price to Owners' Earnings ratio is -21.82
Legend Biotech Corp ( LEGN ) EBITDA TTM ($MM) is -53.32
Legend Biotech Corp ( LEGN ) EBITDA Margin is -135.86%
Capital Allocation:
Legend Biotech Corp ( LEGN ) has paid 0.00 dividends per share and bought back -203.670347 million shares in the past 12 months
Legend Biotech Corp ( LEGN ) has increased its debt by 32.411 million USD in the last 12 months
Capital Structure:
Legend Biotech Corp ( LEGN ) Interest-bearing Debt ($MM) as of last quarter is 320
Legend Biotech Corp ( LEGN ) Annual Working Capital Investments ($MM) are -9
Legend Biotech Corp ( LEGN ) Book Value ($MM) as of last quarter is 1339
Legend Biotech Corp ( LEGN ) Debt/Capital as of last quarter is 23%
Other Balance Sheet Stats:
Legend Biotech Corp ( LEGN ) has 963 million in cash on hand as of last quarter
Legend Biotech Corp ( LEGN ) has 175 million of liabilities due within 12 months, and long term debt 275 as of last quarter
Legend Biotech Corp ( LEGN ) has 362 common shares outstanding as of last quarter
Legend Biotech Corp ( LEGN ) has 0 million USD of preferred stock value
Academic Scores:
Legend Biotech Corp ( LEGN ) Altman Z-Score is 24.01 as of last quarter
Legend Biotech Corp ( LEGN ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
Legend Biotech Corp ( LEGN ) largest shareholder is Holocene Advisors, LP owning 1269264 shares at 70.95 ($MM) value
(an insider) shares of Legend Biotech Corp ( LEGN ) for the amount of $ on
1.37% of Legend Biotech Corp ( LEGN ) is held by insiders, and 40.88% is held by institutions
Legend Biotech Corp ( LEGN ) went public on 2020-06-05
Other Legend Biotech Corp ( LEGN ) financial metrics:
FCF:-437.25
Unlevered Free Cash Flow:-478.45
EPS:-0.69
Operating Margin:-96.18
Gross Profit Margin:54.72
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-18.57
Beta:0.00
Buffet's Owners Earnings:-365.26
Price to Owner's Earnings:-21.82
About Legend Biotech Corp ( LEGN ) :
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia , gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Gen Biotech Corporation.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.